Boston Scientific (BSX)
(Delayed Data from NYSE)
$87.59 USD
-1.18 (-1.33%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $87.59 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$87.59 USD
-1.18 (-1.33%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $87.59 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum C VGM
Zacks News
Boston Scientific Acquires EMcision, Boosts Endoscopy Unit
by Zacks Equity Research
Boston Scientific (BSX) adopts initiatives to strengthen the Endoscopy business.
Zacks Industry Outlook Highlights: Abbott, Becton and Dickinson, Stryker, Varian Medical and Boston Scientific
by Zacks Equity Research
Zacks Industry Outlook Highlights: Abbott, Becton and Dickinson, Stryker, Varian Medical and Boston Scientific
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific
Millipede to Aid Boston Scientific, LOTUS Relaunch Lag Ails
by Zacks Equity Research
Boston Scientific's (BSX) major Millipede investment might cement the company's position in the emerging mitral regurgitation field under its structural heart business.
Boston Scientific's (BSX) Q4 Earnings In Line, Sales Top
by Zacks Equity Research
Boston Scientific (BSX) has posted impressive fourth quarter results by delivering revenue growth across all segments in Q4.
Medical Device Stocks Earnings Due on Feb 1: BSX, BAX & More
by Zacks Equity Research
As part of the amended tax policy, corporate tax rates are lowered to 21% from 35%, offering a huge relief to medical device giants.
Boston Scientific's (BSX) Millipede Deal Aids MR Business
by Zacks Equity Research
Boston Scientific (BSX) claims the Millipede IRIS annuloplasty ring to be highly customizable to a specific patient's anatomy and disease state.
Will WATCHMAN Boost Boston Scientific's (BSX) Q4 Earnings?
by Zacks Equity Research
Boston Scientific (BSX) witnesses improvement in IC arm on an innovative portfolio and robust commercial teams. The WATCHMAN platform is likely to impress with another solid quarterly performance.
Boston Scientific's Positive SCS Trial Aids Neuromodulation
by Zacks Equity Research
Boston Scientific's (BSX) WHISPER RCT data demonstrates that sub-perception and paresthesia-based SCS therapies deliver superior results when applied as a combo regimen.
Boston Scientific Fortifies Pain Therapy Arm With FDA Nod
by Zacks Equity Research
Boston Scientific (BSX) claims its Spectra WaveWriter Spinal Cord Stimulator System to combine both paresthesia-based and sub-perception therapies to target a specific area of pain.
MedTech Tax Resumes in 2018, 3 Stocks to Suffer
by Zacks Equity Research
Sectors that are likely to be hampered the most by the re-imposition of the medical device tax are X-ray and MRI machines, surgical instruments and pacemakers.
Boston Scientific Rises 8.3% on Upbeat 4Q Preliminary Sales
by Zacks Equity Research
Boston Scientific (BSX) pulls out all the stops to strengthen its core business as well as invest more in the global markets. This also gets reflected in its preliminary sales results.
Boston Scientific (BSX) Surges: Stock Moves 8.3% Higher
by Zacks Equity Research
Boston Scientific (BSX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
New Products Aid Boston Scientific, LOTUS Relaunch Lag Ails
by Zacks Equity Research
Boston Scientific (BSX) grows on product launches and international expansion. LOTUS relaunch delay hurts sales.
Boston Scientific Receives FDA Nod for Vercise DBS System
by Zacks Equity Research
Boston Scientific (BSX) forges ahead with initiatives to boost DBS portfolio under Neuromodulation business.
Boston Scientific (BSX) Shares Drop on LOTUS Relaunch Delay
by Zacks Equity Research
Boston Scientific (BSX) announces a delay in deadline for the commercial return of the LOTUS Edge Aortic Valve System in Europe. Following this news, share price declines.
The Zacks Analyst Blog Highlights: Baxter International, BostonScientific, Intuitive Surgical and Becton and Dickinson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Baxter International, BostonScientific, Intuitive Surgical and Becton and Dickinson
Trump Focuses on APAC: 4 MedTech Stocks to Watch
by Zacks Equity Research
Considering Trump's growing focus on APAC, the region seems to be poised to yield accretive returns over the long term. Favorable MedTech trends in APAC hold promise.
Boston Scientific's (BSX) Q3 Earnings In Line, Sales Top
by Zacks Equity Research
Boston Scientific (BSX) has posted impressive Q3 results by delivering revenue growth across all segments.
Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.
MedTech Stock Q3 Earnings Roster for Oct 26: BSX, RMD & More
by Zacks Equity Research
Investors are concerned about the Medical sector that saw a lot of struggle during the first nine months of the year, thanks to the political change and the ongoing policy-restructuring related battle.
EW vs. BCR: Which Stock is Poised for Better Q3 Earnings?
by Zacks Equity Research
Political turmoil and the health policy related battle apart, majority of the MedTech stocks' bottom line is likely to be hurt in the third quarter on escalating costs induced by consecutive hurricanes and Mexico earthquakes.
Will Recall Issue Hurt Boston Scientific (BSX) Q3 Earnings?
by Zacks Equity Research
Although Boston Scientific's (BSX) recent $435-million acquisition of Symetis SA might drive its IC business, the company's full recovery post a primary product recall may however, take time.
Boston Scientific Grows on New Products, Currency Woe Ails
by Zacks Equity Research
Boston Scientific (BSX) is gaining traction on product launch and accretive acquisitions. Yet an unfavorable currency movement is a major dampener.
Boston Scientific's Apama Deal to Boost Electrophysiology Arm
by Zacks Equity Research
Boston Scientific's (BSX) Apama Medical addition is expected to strengthen its suite of arrhythmia solutions under the Electrophysiology sub-segment.